Latest News Archive

Please select Category, Year, and then Month to display items

Department of Nuclear Medicine reports successful treatment of patient with advanced stage prostate cancer

30 August 2022 | Story André Damons | Photo André Damons

UFS Nuclear Medicine — The team of doctors in the Department of Nuclear Medicine behind the success story are, from the left (standing): Dr Osayande Evbuomwan, nuclear medicine specialist and Senior Lecturer; Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS; and Dr Walter Endres, nuclear medicine registrar. In front is Dr Tebatso Tebeila, nuclear medicine registrar.

The University of the Free State (UFS) Department of Nuclear Medicine is proud to announce the successful treatment outcome of a patient with metastatic castrate-resistant prostate cancer (MCRPC) – an advanced stage of prostate cancer – by using Lutetium 177 PSMA (Lu-177 PSMA) therapy. This was initially a case of advanced stage prostate cancer, which had failed first-line chemotherapy, leaving little or no other treatment options.

This is a proud and happy moment for the department and the UFS, which started this treatment just over a year ago. The university and the Free State province are now joining other South African medical universities, such as the University of Pretoria, and other provinces in using this method to treat MCRPC patients. Lutetium 177 PSMA (Lu-177 PSMA) therapy is used on MCRPC patients who are not eligible for chemotherapy or have failed first- or second-line chemotherapy.

Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS, says the department is proud to be able to offer this treatment option to some of these patients. “It is a big win for the Free State and our oncology patients to be able to offer these expert services.” The UFS and Universitas Academic Hospital have now been able to join up with other academic institutions and hospitals in other provinces to offer these services. So far, three patients have been offered this therapeutic option, with the third patient currently undergoing his treatment.

Funds and equipment for proper treatment selection are needed

The expertise is no longer an issue for the UFS, as Dr Osayande Evbuomwan, nuclear medicine specialist and consultant, was trained and exposed to this therapy at the University of the Witwatersrand during his training as a nuclear medicine resident. Current registrars in the Department of Nuclear Medicine at the UFS are also being trained in the application of this treatment modality. However, proper patient selection is key in the management of these cases with Lu 177 PSMA. Without a PET/CT camera, it is challenging to appropriately select the patients who are most likely to respond to this therapy. This is an example of how PET/CT is crucial in the management and monitoring of oncology patients.

Both Drs Engelbrecht and Evbuomwan hope that the training of more registrars will increase their department’s capacity to treat more patients. They also hope that funds will be made available to acquire a much-needed PET/CT camera, which will greatly assist them in identifying the correct patients in need of this treatment.

With the permission of the patient, the images above show the dramatic treatment response following Lu-177 PSMA therapy. The images on the left show widespread bone disease from the prostate cancer, including the skull. The images on the right show the dramatic response after completing four cycles of Lu 177 PSMA, with the normal excretion of the radiotracer seen in the liver, kidneys, and bladder.

Treatment puts the department, UFS, and hospital on the map

According to Dr Evbuomwan, the ability to administer this treatment puts the department, the UFS, and the hospital on the map, alongside other top universities within and outside the country. Says he: “It also creates an avenue for us to gather data for training, research purposes, and publications. We are now able to offer a promising, safe, and highly efficacious therapy for patients with MCRPC in the Free State. Some of these patients will no longer have to travel to other provinces to receive this treatment.”

“We are also well aware that not every patient will respond this way; however, proper patient selection is key in identifying responders – an area that is still being researched. We also do not know how long these patients will have their disease under control after the treatment. Nuclear medicine’s greatest cancer therapy success story is the treatment of well-differentiated thyroid cancer with radioactive iodine.”

“After treatment, most of these patients remain cancer-free for a very long period of time, if not for life. With continuing research in the field of MCRPC radioligand therapy, we aim to improve the treatment modality, hopefully getting it to the success level of thyroid cancer therapy.”

News Archive

Moshoeshoe's legacy lives on in university's project: City Press - 2 May 2004

2004-10-14

CITY PRESS 2 MAY 2004 P8

NEWS

JOHANNESBURG FINAL

Moshoeshoe's legacy lives on in university's project

MATEFU MOKOENA

DRUMS were beaten and the sounds of traditional songs reverberated through corridors of the University of the Free State (UFS) as Basotho students gathered at the campus over the weekend to launch a project honouring their late great king, Moshoeshoe.

The launch was organised by the Lesotho Students Association and UFS management and was blessed by King Letsie III of Lesotho.

According to UFS rector and vicechancellor, Professor Frederick Fourie, the aim of the project is to make the legacy of Moshoeshoe a living part of the university.

He said the Moshoeshoe project will include a television documentary on his life as well as an anthology of creative writings, including prose and poetry, about him.

A television documentary is already being filmed and will be screened during an international conference at UFS in October.

Fourie said the university, as part of the project, is looking at the possibility of starting an annual Moshoeshoe memorial lecture that will focus on African leadership, nationbuilding and reconciliation.

He said the university would introduce a PhD-level research course into the life and legacy of Moshoeshoe.

The university management has also taken a decision to erect a statue of Moshoeshoe on the campus.

Fourie said the project was launched after the UFS delegation, led by him, met Letsie III.

"He wanted us to ensure the legacy of Moshoeshoe is honoured and treated with the respect he deserves."

His legacy "must live on -- not only for the Basotho, but for all South Africans, black and white, and for the entire African continent", he said.

"Living out such a legacy is indeed a fitting contribution to the New Partnership for Africa's Development (Nepad) and to the maturing democracy that is being built here in South Africa," said Fourie.

He emphasised Moshoeshoe was and remains a model of African leadership.

Fourie said Moshoeshoe's diplomacy and commitment to peace put him on a par with former president Nelson Mandela as a statesman.

It is Fourie's dream that, through this project, the UFS will be able to give real meaning to words such as reconciliation, respect for the diversity of languages and cultures and the unity that is needed to build a democratic nation.

The Lesotho Students Association secretary, Sofonea Shale, said for an institution like the UFS to honour Moshoeshoe demonstrates that he was a great leader. "For Basotho students, the project is very significant as it clearly defines who we are and what we stand for.

"We believe the research into the legacy of our great king Moshoeshoe will open doors for more research into the life of Basotho in general.

"Africa as a whole can learn from his leadership style," he said.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept